• Users Online: 440
  • Print this page
  • Email this page
Year : 2020  |  Volume : 11  |  Issue : 3  |  Page : 131-136

Dipeptidyl-peptidase-4 inhibitors in type 2 diabetes and COVID-19: From a potential repurposed agent to a useful treatment option

1 Department of Diabetes & Endocrinology, G.D Hospital and Diabetes Institute, Kolkata, India
2 Department of Gynecology & Obstetrics, G.D Hospital and Diabetes Institute, Kolkata, India

Correspondence Address:
Dr. Awadhesh Kumar Singh
Department of Diabetes & Endocrinology, GD Hospital and Diabetes Institute, Kolkata, West Bengal.
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/JOD.JOD_53_20

Rights and Permissions

Dipeptidyl-peptidase-4 inhibitors (DPP-4Is) are very commonly prescribed antidiabetic agents in the treatment of type 2 diabetes owing to its modest ability to reduce blood glucose without ensuing any hypoglycemia and weight gain. Many experts have advised continuing DPP-4Is in patient with type 2 diabetes with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 2019 (COVID-19). In addition, several researchers have proposed DPP-4Is to be used as a repurposed agent for COVID-19 not only for the patients with diabetes but also for those without diabetes. We aimed to review as to what could be the reason behind this approach and how does the use of DPP-4Is alter the outcome in patients with type 2 diabetes and COVID-19.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded318    
    Comments [Add]    
    Cited by others 3    

Recommend this journal